Loading...
Market
What will be ponsegromab's market approval status in the US and EU by December 31, 2025?
2
Resolution / Starting Odds
Approved in the US only • 25%
Approved in the EU only • 25%
Approved in both US and EU • 25%
Not approved in either region • 25%
Official press releases from regulatory agencies (FDA, EMA, etc.)
Story
Pfizer's Ponsegromab Shows Promise in Phase 2 Study for Cancer Cachexia at ESMO24
Sep 14, 2024, 12:48 PM
Pfizer presented positive data from a Phase 2 study of its experimental drug, ponsegromab, at the ESMO24 conference. The drug showed promising results in treating cancer cachexia, a life-threatening condition characterized by severe weight loss and muscle wasting, which currently has no FDA-approved treatments. The study demonstrated that ponsegromab increased weight, improved appetite, and allowed patients to increase their physical activity. This development offers fresh hope for cancer patients suffering from this debilitating condition.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
FDA Approval • 25%
EMA Approval • 25%
Additional Phase 3 Trials • 25%
Other • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Approved by FDA • 25%
Approved by EMA • 25%
Approved by both FDA and EMA • 25%
Not approved • 25%
Approved • 25%
Rejected • 25%
Pending • 25%
Withdrawn • 25%
Yes • 50%
No • 50%
FDA approval • 25%
FDA rejection • 25%
Conditional approval • 25%
No decision • 25%
